Zeitschriftenaufsatz
|
2013
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response.
Autor:in
Hannesdóttir, Lára; Tymoszuk, Piotr; Parajuli, Nirmala; Wasmer, Marie-Helene; Philipp, Sonja; Daschil, Nina; Datta, Sebak; Koller, Johann-Benedikt; Tripp, Christoph H; Stoitzner, Patrizia; Müller-Holzner, Elisabeth; Wiegers, Gerrit Jan; Sexl, Veronika; Villunger, Andreas; Doppler, Wolfgang;
Publikationen als Autor:in / Herausgeber:in der Vetmeduni
Journal
Schlagwörter
Animals; Antigens, Neoplasm/immunology; Breast Neoplasms/drug therapy*; Breast Neoplasms/immunology; CD8-Positive T-Lymphocytes/drug effects*; CD8-Positive T-Lymphocytes/immunology; Cell Movement/drug effects; Cell Movement/genetics; Cells, Cultured; Chemotaxis/drug effects; Disease Models, Animal; Doxorubicin/administration & dosage*; Female; Humans; Interferon-gamma/metabolism; Lymphocyte Activation/drug effects; Lymphocyte Activation/genetics; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Protein Kinase Inhibitors/administration & dosage*; Quinazolines/administration & dosage*; Rats; Receptor, Epidermal Growth Factor/antagonists & inhibitors; Receptor, erbB-2/antagonists & inhibitors; Receptor, erbB-2/genetics; Receptor, erbB-2/metabolism; STAT1 Transcription Factor/genetics; STAT1 Transcription Factor/immunology; STAT1 Transcription Factor/metabolism*;
Dokumententyp
Originalarbeit
ISSN/eISSN
0014-2980 -
10.1002/eji.201242505
WoS ID
PubMed ID